Annovis Bio begins pivotal phase 3 Alzheimer's drug trial
MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...
The Next Web2d
Will AI revolutionise drug development? Researchers say it depends on how it’s used
A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.